<DOC>
	<DOC>NCT01342380</DOC>
	<brief_summary>Obtain phenotypic data and a DNA/blood sample from mood disorder patients undergoing pioglitazone or quetiapine XR treatment as a part of an IRB approved clinical trial conducted at the Mood Disorders Program. Pioglitazone treatment is examined in metabolic syndrome comorbid with bipolar depression (IRB # 07-08-24) and unipolar depression (IRB # 07-07-20). Quetiapine XR treatment is examined in generalized anxiety disorder comorbid with bipolar depression (IRB # 10-06-19) and unipolar depression (IRB # 12-01-29). Please refer to the respective IRB protocols for more information.</brief_summary>
	<brief_title>Pioglitazone and Quetiapine XR Pharmacogenetic Study</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Must have participated in IRB protocols 100619, 120729, 070720, and 070824 Patient must give consent to participate, sign and date the IRB approved written informed consent form prior to the initiation of any procedures for this study Patient must be diagnosed with Bipolar Disorder or Major Depressive Disorder Patient must be at least 18 years old Patient must be willing to give a blood sample Patient lacks the capacity to provide informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>